Merck Announces Collaboration with the American Diabetes Association to Educate Adults with Diabetes About Increased Risk for...
March 26 2015 - 8:30AM
Business Wire
Merck (NYSE:MRK), known as MSD outside of the United States and
Canada, today announced a collaboration with the American Diabetes
Association (ADA). The collaboration aims to educate adults with
diabetes about their increased risk for potentially serious health
problems, including pneumococcal pneumonia, influenza (flu) and
hepatitis B, making it important for people with Type 1 or Type 2
diabetes to talk to their health care professional (HCP) about
these diseases.
“It is important for health care providers to help their
diabetic patients understand their increased risk for infections,
and to discuss the best approach to managing this increased risk.
For example, adults with diabetes are three times more likely to
develop pneumococcal pneumonia compared to adults without
diabetes,” said Mel Kohn, M.D., M.P.H., medical director, Merck.
“There is therefore a need to increase conversations by HCPs on the
levels of risk for these infections in this patient
population.”
According to the Centers for Disease Control and Prevention
(CDC), 29.1 million people, or 9.3%, of the U.S. population have
diabetes (it is estimated that of this population, 21 million
people are diagnosed and 8.1 million people remain undiagnosed).
Each year, 1.7 million new cases of diabetes are diagnosed in
people aged 20 years and older.
The ADA’s Professional Practice Committee’s yearly Standards of
Medical Care in Diabetes notes that ongoing patient self-management
education and support are critical to preventing acute
complications, and reducing the risk of long-term complications.
The Committee also notes that good communication with HCPs can help
people with diabetes feel in control and respond to the challenges
that come with the disease.
“Our work with Merck will help disseminate the very important
message to the diabetes community that keeping up-to-date on
recommended HCP appointments, and being aware of risk factors and
how to minimize additional complications are critical to
maintaining good health,” said Jane Chiang, M.D., senior vice
president, medical and community affairs, American Diabetes
Association.
About Merck
Today's Merck is a global healthcare leader working to help the
world be well. Merck is known as MSD outside the United States and
Canada. Through our prescription medicines, vaccines, biologic
therapies and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative health
solutions. We also demonstrate our commitment to increasing access
to healthcare through far-reaching policies, programs and
partnerships. For more information, visit www.merck.com and connect
with us on Twitter, Facebook and YouTube.
About The American Diabetes Association
The American Diabetes Association is leading the fight to Stop
Diabetes and its deadly consequences and fighting for those
affected by diabetes. The Association funds research to prevent,
cure and manage diabetes; delivers services to hundreds of
communities; provides objective and credible information; and gives
voice to those denied their rights because of diabetes. Founded in
1940, the ADA’s mission is to prevent and cure diabetes and to
improve the lives of all people affected by diabetes.
For more information please call the American Diabetes
Association at 1-800-DIABETES (800-342-2383) or visit
www.diabetes.org. Information from both these sources is available
in English and Spanish.
Merck Forward-Looking Statement
This news release includes “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. These statements
are based upon the current beliefs and expectations of Merck’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and healthcare
legislation in the United States and internationally; global trends
toward healthcare cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; Merck’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of Merck’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
Merck undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in Merck’s 2014 Annual
Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission(SEC) available at the SEC’s
Internet site (www.sec.gov).
MerckMedia:Pamela Eisele, 267-305-3558orSkip Irvine,
215-652-6059orInvestors:Justin Holko, 908-740-1879
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024